Protagonist Therapeutics, Inc. PTGX R2K
Healthcare · Biotechnology · United States
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
READ MORE ›$99.56
+109.73% 1Y
Market & Price
Market Cap
$6.40B
Current Price
$99.56
High / Low (52W)
$105.98 / $47.47
Beta
1.88
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$10.21
Price to Book
9.76
P/S
86.45
EV/EBITDA
-41.59
Dividend Yield
-
Profitability & Returns
ROCE
-25.39%
ROE
-17.06%
ROA
-12.37%
Profit Margin
-
Op Margin
-6.47%
EPS (Latest Qtr)
$0.05
EPS (TTM)
$-1.81
Balance Sheet & Liquidity
Debt/Equity
1.49
Quick Ratio
17.51
Current Ratio
17.76
Debt
$9.78M
Total Assets
$668.19M
Current Assets
$577.57M
Working Capital
$532.13M
Ownership
Promoter Holding
0.71%
Chg in Prom Hold
-
FII / Inst Holding
125.23%
Chg in FII Hold
0.01%
Financial Snapshot
Enterprise Value
$5.86B
Total Revenue (TTM)
$74.06M
EBITDA
$-141.02M
Free Cash Flow
$-77.66M
Operating Cash Flow
$-116.64M
Shares Outstanding
64.31M
Gross Margin
100.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
20.07%
Profit 5Y
-0.72%
Revenue (YoY)
99.00%
Earnings (YoY)
-
PROS
- Compounding revenue at 20.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -0.7% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PTGX Protagonist Therapeutics, Inc. R2K | 99.56 | - | $6.40B | - | -25.39% | -17.06% | 20.07% | -0.72% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | - | - | - | 8.78M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.32M | 5.55M | 4.71M | 7.44M | 56.37M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.63M | 47.59M | 51.13M | 57.79M | 60.02M |
| Operating Income | -2.69M | -3.08M | -4.02M | -5.00M | -7.04M | -7.09M | -7.14M | -11.40M | -14.27M | -15.13M | -4.98M | -3.51M | -8.23M | -9.24M | -9.39M | -15.41M | -14.65M | -31.41M | -17.17M | -17.30M | -19.70M | -18.22M | -7.77M | -24.02M | -30.88M | -33.93M | -21.11M | -41.44M | -32.30M | -36.02M | -42.35M | -38.33M | 206.31M | -38.79M | -41.45M | -19.31M | -42.04M | -46.42M | -50.35M | -3.65M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.07M | -41.74M | -46.06M | -49.98M | -3.24M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.65M | -34.60M | -39.34M | -43.72M | 2.28M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 172.00K | 0 | 666.00K | -1.50M |
| Net Income | -2.70M | -3.22M | -3.45M | -5.49M | -11.75M | -7.10M | -7.08M | -11.25M | -14.10M | -14.98M | -4.83M | -3.05M | -7.66M | -8.66M | -8.73M | -13.87M | -14.10M | -29.17M | -16.41M | -17.50M | -20.08M | -19.42M | -7.76M | -24.00M | -30.84M | -33.80M | -20.93M | -41.04M | -31.23M | -33.73M | -38.46M | -34.10M | 207.34M | -30.62M | -33.21M | -11.65M | -34.77M | -39.34M | -44.38M | 3.78M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.54 | -0.69 | -0.70 | -0.43 | -0.84 | -0.64 | -0.67 | -0.68 | -0.58 | 3.26 | -0.50 | -0.54 | -0.19 | -0.55 | -0.62 | -0.69 | 0.05 |
| R&D Expense | - | 2.30M | 3.16M | - | 5.62M | 5.70M | 5.56M | - | 11.28M | 12.01M | 11.17M | - | 15.37M | 17.73M | 12.14M | - | 12.44M | 19.36M | 17.29M | - | 18.77M | 20.26M | 15.99M | 24.25M | 26.43M | 36.96M | 36.32M | 34.61M | 25.40M | 27.42M | 33.18M | 30.66M | 33.73M | 33.52M | 35.97M | 35.89M | 37.04M | 40.00M | - | 46.74M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 20.06M | 30.93M | 231.00K | 28.63M | - | 26.58M | 60.00M | 434.43M | 46.02M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | 157.95M | 153.65M | 181.59M | 204.14M |
| Operating Income | -9.32M | -14.79M | -32.67M | -37.90M | -42.27M | -80.52M | -64.52M | - | -131.37M | -93.65M | 252.84M | -158.13M |
| EBITDA | - | - | - | - | - | - | - | - | -130.34M | -92.67M | 253.67M | -156.85M |
| Interest Expense | - | - | - | - | - | - | - | 0 | 0 | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | -127.39M | -78.95M | 279.41M | -129.31M |
| Tax Provision | - | - | - | - | - | - | - | - | 0 | 0 | 4.22M | 838.00K |
| Net Income | -11.07M | -14.86M | -37.18M | -36.96M | -38.92M | -77.19M | -66.15M | - | -127.39M | -78.95M | 275.19M | -130.15M |
| Diluted EPS | - | - | - | - | - | - | -1.92 | - | -2.60 | -1.39 | 4.23 | -2.05 |
| R&D Expense | 7.46M | 11.83M | 25.70M | 46.18M | 59.50M | 65.00M | 74.51M | 126.01M | 126.22M | 120.16M | 138.13M | 159.29M |
Compounded Sales Growth
| 5 Years: | 20.07% |
| 1 Year: | 99.00% |
Compounded Profit Growth
| 5 Years: | -0.72% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +109.73% |
| 6 Months: | +10.79% |
| 3 Months: | +8.12% |
| 1 Month: | +1.06% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 14.85M | 93.99M | 163.73M | 139.47M | 154.92M | 324.47M | - | 247.93M | 357.95M | 744.73M | 668.19M |
| Current Assets | - | - | - | - | - | - | - | - | - | 243.08M | 355.58M | 591.64M | 577.57M |
| Cash & Equivalents | 8.46M | 9.32M | 4.05M | 21.08M | 106.03M | 82.23M | 33.01M | 117.36M | - | 125.74M | 186.73M | 97.25M | 128.39M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | 52.00K | 10.33M | 168.49M | 4.50M |
| Total Liabilities | - | - | 5.25M | 6.43M | 43.10M | 26.96M | 74.95M | 44.86M | - | 32.32M | 21.27M | 69.43M | 53.48M |
| Current Liabilities | - | - | 3.13M | 6.43M | 42.55M | 26.16M | 35.41M | 40.24M | - | 31.18M | 21.27M | 47.40M | 45.44M |
| Long Term Debt | - | - | - | - | - | - | 9.79M | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | 3.66M | 1.14M | 10.87M | 10.32M |
| Total Equity | -1.39M | -12.62M | -27.40M | 87.56M | 120.63M | 112.52M | 79.96M | 279.61M | - | 215.61M | 336.68M | 675.29M | 614.71M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 49.34M | 57.71M | 61.04M | 62.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -14.38M | -29.97M | 3.87M | -49.95M | -41.53M | -72.48M | - | -108.14M | -70.24M | 184.15M | 57.67M |
| Investing Cash Flow | - | -8.26M | -59.33M | 15.82M | 2.21M | -53.71M | -90.97M | - | 91.47M | -39.26M | -299.48M | -49.33M |
| Financing Cash Flow | - | 17.42M | 106.31M | 65.55M | 24.11M | 46.04M | 247.63M | - | 18.84M | 170.48M | 25.85M | 22.86M |
| Capital Expenditure | -299.00K | -399.00K | -347.00K | -666.00K | -486.00K | -967.00K | -471.00K | - | -795.00K | -609.00K | -1.35M | -1.59M |
| Free Cash Flow | - | -14.78M | -30.32M | 3.21M | -50.43M | -42.49M | -72.95M | - | -108.93M | -70.84M | 182.80M | 56.08M |
| Net Change in Cash | - | - | - | - | - | - | - | - | 2.17M | 60.98M | -89.48M | 31.20M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -188.9% | -136.7% | -34,857.6% | -225.4% | - | -494.2% | -156.1% | 58.2% | -343.6% |
| Net Margin % | - | - | - | -184.2% | -125.9% | -33,414.3% | -231.1% | - | -479.3% | -131.6% | 63.3% | -282.8% |
| ROE % | 87.7% | 54.2% | -42.5% | -30.6% | -34.6% | -96.5% | -23.7% | - | -59.1% | -23.5% | 40.8% | -21.2% |
| ROCE % | - | -126.2% | -37.3% | -31.3% | -37.3% | -67.4% | -22.7% | - | -60.6% | -27.8% | 36.3% | -25.4% |
Shareholding Pattern
Insiders
0.71%
Institutions
125.23%
Public Float
126.13%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.21% | 9.78M | $973.63M |
| 2 | Farallon Capital Management LLC | 9.87% | 6.35M | $632.10M |
| 3 | UBS Group AG | 8.05% | 5.18M | $515.50M |
| 4 | RTW Investments LP | 7.87% | 5.06M | $503.68M |
| 5 | Wellington Management Group, LLP | 5.60% | 3.60M | $358.38M |
| 6 | Vanguard Portfolio Management LLC | 5.41% | 3.48M | $346.59M |
| 7 | State Street Corporation | 4.85% | 3.12M | $310.30M |
| 8 | Janus Henderson Group PLC | 4.50% | 2.89M | $287.88M |
| 9 | Vanguard Capital Management LLC | 4.36% | 2.81M | $279.35M |
| 10 | Johnson & Johnson | 3.81% | 2.45M | $243.84M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PTGX
No recent headlines available.